This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Bacainn Biotherapeutics, Ltd.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Manuel Navia: Innovator in Inflammasome-Mediated Lung Disease Treatment
Introduction
Manuel Navia is a notable inventor based in Lexington, MA (US). He has made significant contributions to the field of biotherapeutics, particularly in the treatment of inflammasome-mediated lung diseases. His innovative work has the potential to impact many lives suffering from these conditions.
Latest Patents
Navia holds a patent for "Probenecid compounds for the treatment of inflammasome-mediated lung disease." This patent discloses methods, compounds, and compositions aimed at treating or preventing inflammasome-mediated diseases or conditions, including those affecting the lungs. His research is crucial in advancing therapeutic options for patients.
Career Highlights
Manuel Navia is currently associated with Bacainn Biotherapeutics, Ltd., where he continues to develop groundbreaking treatments. His expertise in the field has positioned him as a key player in biotherapeutics, focusing on innovative solutions for complex health issues.
Collaborations
Navia collaborates with talented individuals such as Chris Murphy and Ronald Farquhar. These partnerships enhance the research and development efforts at Bacainn Biotherapeutics, Ltd., fostering an environment of innovation and discovery.
Conclusion
Manuel Navia's contributions to the treatment of inflammasome-mediated lung diseases exemplify the impact of dedicated inventors in the field of biotherapeutics. His work not only advances medical science but also offers hope to those affected by these challenging conditions.